
Jan 29 (Reuters) - Fractyl Health Inc GUTS.O:
FRACTYL HEALTH ANNOUNCES COMPELLING 6-MONTH RANDOMIZED REMAIN-1 MIDPOINT DATA SHOWING DURABLE WEIGHT MAINTENANCE WITH REVITA® AFTER GLP-1 DISCONTINUATION
FRACTYL HEALTH INC - REVITA-TREATED PATIENTS SHOW 4.5% WEIGHT REGAIN VERSUS 7.5% SHAM
FRACTYL HEALTH INC - REQUESTED FDA FEEDBACK ON REVITA DE NOVO PATHWAY
FRACTYL HEALTH INC: EXPECTS FDA FEEDBACK REGARDING POTENTIAL FOR USE OF DE NOVO PATHWAY IN Q2 OF 2026
FRACTYL HEALTH INC - REVITA SHOWS 4.2% WEIGHT REGAIN VERSUS 13.3% SHAM